Dopamine D1-like receptors agonist SKF 38393 increases cFos expression in the paraventricular nucleus of the hypothalamus - Impact of acute and chronic cocaine

Journal of Physiology and Pharmacology

Volumn 59, Issue 3, 2008, Pages 425-440

  Chocyk, A ^a   Czyrak, A ^a   Wedzony K ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

cFos; Cocaine; Corticotropin releasing factor; Dopamine D1 like receptors; Oxytocin; Paraventricular nucleus of the hypothalamus; Vasopressin

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; COCAINE; CORTICOTROPIN RELEASING FACTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DRUG VEHICLE; OXYTOCIN; PROTEIN C FOS; VASOPRESSIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; CHRONIC DRUG ADMINISTRATION; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EXPOSURE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; COCAINE; CORTICOTROPIN-RELEASING HORMONE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENES, FOS; IMMUNOHISTOCHEMISTRY; MALE; OXYTOCIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; SYNAPTIC TRANSMISSION; VASOPRESSINS;

EID: 53649095928     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Clouet D, Asghar K, Brown R. Mechanisms of Cocaine Abuse and Toxicity. In NIDA Resaerch Monograph 88. 1988, pp 1-354.
2. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129.
3. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991; 14: 299-302.
4. Roberts DC, Koob GF, Klonoff P, Fibiger HC. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav 1980; 12: 781-787.
5. Roberts DC, Koob GF. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav 1982; 17: 901-904.
6. Beveridge TJ, Smith HR, Nader MA, Porrino LJ. Functional effects of cocaine self-administration in primate brain regions regulating cardiovascular function. Neurosci Lett 2004; 370: 201-205.
7. Kiritsy-Roy JA, Halter JB, Gordon SM, Smith MJ, Terry LC. Role of the central nervous system in hemodynamic and sympathoadrenal responses to cocaine in rats. J Pharmacol Exp Ther 1990; 255: 154-160.
8. Mello NK, Mendelson JH. Cocaine's effects on neuroendocrine systems: clinical and preclinical studies. Pharmacol Biochem Behav 1997; 57: 571-599.
9. Deroche V, Piazza PV, Casolini P, Maccari S, Le Moal M, Simon H. Stress-induced sensitization to amphetamine and morphine psychomotor effects depend on stress-induced corticosterone secretion. Brain Res 1992; 598: 343-348.
10. Erb S, Salmaso N, Rodaros D, Stewart J. A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl) 2001; 158: 360-365.
11. Goeders NE, Guerin GF. Role of corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 1996; 64: 337-348.
12. Iversen S, Iversen L, Saper CB. The autonomic nervous system and the hypothalamus. In Principle of Neural Science, ER Kandel, JH Schwartz, TM Jessel (eds). New York, McGraw-Hill, 2000, pp. 960-981.
13. Swanson LW, Sawchenko PE. Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology 1980; 31: 410-417.
14. Armstrong WE. Hypothalamic supraoptic and paraventricular nuclei. In The Rat Nervous System, G Paxinos (ed). New York, Academic Press, 1995, pp. 377-390.
15. Swanson LW, Kuypers HG. The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol 1980; 194: 555-570.
16. Day HE, Campeau S, Watson SJ, Jr., Akil H. Expression of alpha(1b) adrenoceptor mRNA in corticotropin-releasing hormone-containing cells of the rat hypothalamus and its regulation by corticosterone. J Neurosci 1999; 19: 10098-10106.
17. Bagdy G. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res 1996; 73: 277-280.
18. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001; 21: 3572-3579.
19. Bartanusz V, Muller D, Gaillard RC, Streit P, Vutskits L, Kiss JZ. Local gamma-aminobutyric acid and glutamate circuit control of hypophyseotrophic corticotropin-releasing factor neuron activity in the paraventricular nucleus of the hypothalamus. Eur J Neurosci 2004; 19: 777-782.
20. Boudaba C, Szabo K, Tasker JG. Physiological mapping of local inhibitory inputs to the hypothalamic paraventricular nucleus. J Neurosci 1996; 16: 7151-7160.
21. Boudaba C, Schrader LA, Tasker JG. Physiological evidence for local excitatory synaptic circuits in the rat hypothalamus. J Neurophysiol 1997; 77: 3396-3400.
22. Borowsky B, Kuhn CM. D1 and D2 dopamine receptors stimulate hypothalamo-pituitary-adrenal activity in rats. Neuropharmacology 1992; 31: 671-678.
23. Eaton MJ, Cheung S, Moore KE, Lookingland KJ. Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 1996; 738: 60-66.
24. Jezova D, Jurcovicova J, Vigas M, Murgas K, Labrie F. Increase in plasma ACTH after dopaminergic stimulation in rats. Psychopharmacology (Berl) 1985; 85: 201-203.
25. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine self-administration appears to be mediated by dopamine uptake inhibition. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 233-239.
26. Borowsky B, Kuhn CM. Monoamine mediation of cocaine-induced hypothalamo-pituitary-adrenal activation. J Pharmacol Exp Ther 1991; 256: 204-210.
27. Saphier D, Welch JE, Farrar GE, Goeders NE. Effects of intracerebroventricular and intrahypothalamic cocaine administration on adrenocortical secretion. Neuroendocrinology 1993; 57: 54-62.
28. Sarnyai Z, Mello NK, Mendelson JH, Eros-Sarnyai M, Mercer G. Effects of cocaine on pulsatile activity of hypothalamic-pituitary-adrenal axis in male rhesus monkeys: neuroendocrine and behavioral correlates. J Pharmacol Exp Ther 1996; 277: 225-234.
29. Zhou Y, Spangler R, Yuferov VP, Schlussmann SD, Ho A, Kreek MJ. Effects of selective D1-or D2-like dopamine receptor antagonists with acute "binge" pattern cocaine on corticotropin-releasing hormone and proopiomelanocortin mRNA levels in the hypothalamus. Brain Res Mol Brain Res 2004; 130: 61-67.
30. Borowsky B, Kuhn CM. Chronic cocaine administration sensitizes behavioral but not neuroendocrine responses. Brain Res 1991; 543: 301-306.
31. Schmidt ED, Tilders FJ, Janszen AW, Binnekade R, De Vries TJ, Schoffelmeer AN. Intermittent cocaine exposure causes delayed and long-lasting sensitization of cocaine-induced ACTH secretion in rats. Eur J Pharmacol 1995; 285: 317-321.
32. Zhou Y, Spangler R, Schlussman SD, Ho A, Kreek MJ. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal. Brain Res 2003; 964: 187-199.
33. Bergman J, Kamien JB, Spealman RD. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav Pharmacol 1990; 1: 355-363.
34. Callahan PM, Appel JB, Cunningham KA. Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology (Berl) 1991; 103: 50-55.
35. Xu M, Hu XT, Cooper DC et al. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 1994; 79: 945-955.
36. Xu M, Guo Y, Vorhees CV, Zhang J. Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res 2000; 852: 198-207.
37. Caine SB, Thomsen M, Gabriel KI et al. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. J Neurosci 2007; 27: 13140-13150.
38. Zhou Y, Spangler R, Ho A, Jeanne KM. Hypothalamic CRH mRNA levels are differentially modulated by repeated 'binge' cocaine with or without D(1) dopamine receptor blockade. Brain Res Mol Brain Res 2001; 94: 112-118.
39. Goeders NE. Stress and cocaine addiction. J Pharmacol Exp Ther 2002; 301: 785-789.
40. Przegalinski E, Filip M, Siwanowicz J, Nowak E. Effect of adrenalectomy and corticosterone on cocaine-induced sensitization in rats. J Physiol Pharmacol 2000; 51: 193-204.
41. Piazza PV, Marinelli M, Jodogne C et al. Inhibition of corticosterone synthesis by Metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration. Brain Res 1994; 658: 259-264.
42. Goeders NE, Guerin GF. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res 1996; 722: 145-152.
43. Erb S, Shaham Y, Stewart J. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 1998; 18: 5529-5536.
44. Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001; 53: 209-243.
45. Parker SL, Crowley WR. Activation of central D-1 dopamine receptors stimulates oxytocin release in the lactating rat: evidence for involvement of the hypothalamic paraventricular and supraoptic nuclei. Neuroendocrinology 1992; 56: 385-392.
46. Piazza PV, Le Moal M. Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Brain Res Rev 1997; 25: 359-372.
47. Czyrak A, Chocyk A, Mackowiak M, Fijal K, Wedzony K. Distribution of dopamine D1 receptors in the nucleus paraventricularis of the hypothalamus in rats: an immunohistochemical study. Brain Res Mol Brain Res 2000; 85: 209-217.
48. Fetissov SO, Meguid MM, Sato T, Zhang LH. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol 2002; 283: R905-R910.
49. Fremeau RT, Jr., Duncan GE, Fornaretto MG et al. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A 1991; 88: 3772-3776.
50. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York, Academic Press, 1998.
51. Mackowiak M, Chocyk A, Fijal K, Czyrak A, Wedzony K. c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Brain Res Mol Brain Res 1999; 71: 358-363.
52. Alonso G, Szafarczyk A, Assenmacher I. Immunoreactivity of hypothalamo-neurohypophysial neurons which secrete corticotropin-releasing hormone (CRH) and vasopressin (Vp): immunocytochemical evidence for a correlation with their functional state in colchicine-treated rats. Exp Brain Res 1986; 61: 497-505.
53. Sofroniew MV. Vasopressin, oxytocin and their related neurophysins. In Handbook of Chemical Neuroanatomy. GABA and Neuropeptides in the CNS, Part I, A Bjorklund, T Hokfelt (eds). New York, Elseviere Sciences, 1985, 4: pp. 93-153.
54. Wedzony K , Chocyk A, Mackowiak M. A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices - immunohistochemical studies. J Physiol Pharmacol 2008; 59: 229-238.
55. Wedzony K, Chocyk A, Kolasiewicz W, Mackowiak M. Glutamatergic neurons of rat medial prefrontal cortex innervating the ventral tegmental area are positive for serotonin 5-HT1A receptor protein. J Physiol Pharmacol 2007; 58: 611-624.
56. Andersen PH, Jansen JA. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol 1990; 188: 335-347.
57. Reavill C, Bond B, Overend P, Hunter AJ. Pharmacological characterization of the discriminative stimulus properties of the dopamine D1 agonist, SKF 81297. Behav Pharmacol 1993; 4: 135-146.
58. Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 2001; 7: 399-414.
59. Bender M, Drago J, Rivkees SA. D1 receptors mediate dopamine action in the fetal suprachiasmatic nuclei: studies of mice with targeted deletion of the D1 dopamine receptor gene. Brain Res Mol Brain Res 1997; 49: 271-277.
60. Moratalla R, Xu M, Tonegawa S, Graybiel AM. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor. Proc Natl Acad Sci U S A 1996; 93: 14928-14933.
61. Chaudhuri A. Neural activity mapping with inducible transcription factors. Neuroreport 1997; 8: v-ix.
62. Rivkees SA, Lachowicz JE. Functional D1 and D5 dopamine receptors are expressed in the suprachiasmatic, supraoptic, and paraventricular nuclei of primates. Synapse 1997; 26: 1-10.
63. Huang Q, Zhou D, Chase K, Gusella JF, Aronin N, DiFiglia M. Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus. Proc Natl Acad Sci U S A 1992; 89: 11988-11992.
64. Herman JP, Figueiredo H, Mueller NK et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary- adrenocortical responsiveness. Front Neuroendocrinol 2003; 24: 151-180.
65. Moratalla R, Elibol B, Vallejo M, Graybiel AM. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 1996; 17: 147-156.
66. Dong Y, Nasif FJ, Tsui JJ et al. Cocaine-induced plasticity of intrinsic membrane properties in prefrontal cortex pyramidal neurons: adaptations in potassium currents. J Neurosci 2005; 25: 936-940.
67. Henry DJ, White FJ. Repeated cocaine administration causes persistent enhancement of D1 dopamine receptor sensitivity within the rat nucleus accumbens. J Pharmacol Exp Ther 1991; 258: 882-890.
68. Zhang XF, Cooper DC, White FJ. Repeated cocaine treatment decreases whole-cell calcium current in rat nucleus accumbens neurons. J Pharmacol Exp Ther 2002; 301: 1119-1125.
69. Henry DJ, White FJ. The persistence of behavioral sensitization to cocaine parallels enhanced inhibition of nucleus accumbens neurons. J Neurosci 1995; 15: 6287-6299.
70. Chen J, Kelz MB, Hope BT, Nakabeppu Y, Nestler EJ. Chronic Fos-related antigens: stable variants of deltaFosB induced in brain by chronic treatments. J Neurosci 1997; 17: 4933-4941.
71. Nye HE, Hope BT, Kelz MB, Iadarola M, Nestler EJ. Pharmacological studies of the regulation of chronic FOS-related antigen induction by cocaine in the striatum and nucleus accumbens. J Pharmacol Exp Ther 1995; 275: 1671-1680.
72. Chocyk A, Czyrak A, Wedzony K. Acute and repeated cocaine induces alterations in FosB/DeltaFosB expression in the paraventricular nucleus of the hypothalamus. Brain Res 2006; 1090: 58-68.
73. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci U S A 2001; 98: 11042-11046.
74. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 1998; 28: 370-490.
75. McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci 2003; 6: 1208-1215.